Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 9;12(1):134.
doi: 10.1186/s40364-024-00678-7.

Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance

Justin R Gregg  1 , Lisa Newcomb  2 , Ranran Wu  3 , Jennifer Dennison  3 , John W Davis  3 , Curtis Pettaway  3 , Louis Pisters  3 , John F Ward  3 , Brian F Chapin  3 , Lisly Chéry  3 , Ahmet Urkmez  3 , Andrew M Fang  3 , Noel Higgason  3 , Patricia Troncoso  3 , Carrie R Daniel  3 , Christopher Logothetis  3 , Timothy C Thompson  3 , Andrew W Hahn  3 , Menghan Liu  2 , Yingye Zheng  2 , Dan W Lin  2 , Samir Hanash  3 , Ehsan Irajizad #  3 , Johannes Fahrmann #  3
Affiliations

Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance

Justin R Gregg et al. Biomark Res. .

Abstract

Background: We previously reported that increases in circulating sphingolipids are associated with elevated risk of biopsy Gleason grade group (GG) upgrading in men on Active Surveillance (AS) for prostate cancer. Here, we aimed to validate these findings and establish a blood-based sphingolipid biomarker panel for identifying men on AS who are at high-risk of biopsy GG upgrading.

Methods: Men diagnosed with low- or intermediate-risk prostate cancer in one of two AS cohorts (CANARY PASS and MDACC) were followed for GG upgrading after diagnostic and confirmatory biopsy. The PASS cohort consisted of 544 patients whereas the MDACC Cohort consisted of 697 patients. The number of patients with GG upgrading during course of study follow-up in the PASS and MDACC cohorts were 98 (17.7%) and 133 (19.1%), respectively. Plasmas collected prior to confirmatory biopsy were used for mass spectrometry-based quantitation of 87 unique sphingolipid species. A neural network layer based on 21 sphingolipids was developed in the CANARY PASS cohort for predicting biopsy GG upgrading. Tertile-based thresholds for low-, intermediate-, and high-risk strata were subsequently developed for the sphingolipid panel as well as a model that combined the sphingolipid panel with PSA density and rate of core positivity on diagnostic biopsy. The resultant models and risk thresholds for GG upgrading were validated in the MDACC cohort. Performance was assessed using Cox proportional hazard models, C-index, AUC, and cumulative incidence curves.

Results: The sphingolipid panel had a HR (per unit standard deviation increase) of 1.36 (95% CI: 1.07-1.70) and 1.35 (95% CI: 1.11-1.64) for predicting GG biopsy upgrading in the PASS and MDACC cohort, respectively. The model that combined the sphingolipid panel with PSA density and rate of core positivity achieved a HR of 1.63 (95% CI: 1.33-2.00) and 1.44 (1.25-1.66), respectively. Tertile-based thresholds, established in the PASS cohort, were applied to the independent MDACC cohort. Compared to the low-risk group, MDACC patients in the high-risk strata had a GG biopsy upgrade HR of 3.65 (95% CI: 2.21-6.02), capturing 50% of the patients that had biopsy upgrading during study follow-up.

Conclusions: The sphingolipid panel is independently associated with GG biopsy upgrading among men in two independent AS cohorts who have previously undergone diagnostic and confirmatory biopsy. The sphingolipid panel, together with clinical factors, provides a potential means for risk stratification to better guide clinical management of men on AS.

Keywords: Active surveillance; biomarker; prostate cancer; sphingolipids.

PubMed Disclaimer

Conflict of interest statement

We note that intellectual property was filed related to this work and is pending.

Figures

Fig. 1
Fig. 1
Cumulative incidence curves for GG biopsy upgrade based on combined model at high-, intermediate-, and low-risk strata in the PASS and MDACC Cohorts. Risk tables, including censoring events, are provided beneath. Censoring was attributed to GG upgrading, prostate cancer treatment, voluntary withdrawal from AS, or loss to follow-up following biopsy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. <ArticleTitle Language=“En”>Clinically localized prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared decision making, and Care options. J Urol. 2018;199(3):683–90. - PubMed
    1. Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33(3):272–7. - PubMed
    1. Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023. - PubMed
    1. Lowenstein LM, Basourakos SP, Williams MD, Troncoso P, Gregg JR, Thompson TC, et al. Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned. Nat Rev Clin Oncol. 2019;16(3):168–84. - PMC - PubMed
    1. Bruinsma SM, Zhang L, Roobol MJ, Bangma CH, Steyerberg EW, Nieboer D, et al. The Movember Foundation’s GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU Int. 2018;121(5):737–44. - PubMed

LinkOut - more resources